Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO 2023)

Tampa, Florida, US 25 March 2023 - 28 March 2023

Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer

23 May 2023 by

Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.

23 May 2023

Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer

15 May 2023 by

Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.

15 May 2023

Adavosertib promise in uterine serous carcinoma dimmed by side effects

28 Apr 2023 by

The oral, small molecule Wee1 kinase inhibitor adavosertib exerts antitumour effects in patients with advanced recurrent or persistent uterine serous carcinoma, but this benefit appears to be limited by the drug’s tolerability, as shown in the single-arm, phase IIb ADAGIO study.

28 Apr 2023

Pembrolizumab plus chemo improves PFS in endometrial cancer regardless of MMR status

22 Apr 2023 by

The addition of pembrolizumab to standard chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, regardless of whether they had mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease, according to the NRG-GY018 trial presented at the SGO 2023.

22 Apr 2023

Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?

20 Apr 2023 by

Mirvetuximab soravtansine (MIRV), an antibody drug conjugate (ADC), showed antitumour activity in women with platinum-resistant ovarian cancer* (PROC) with high folate receptor alpha (FRα) expression, findings from the phase III SORAYA study have shown.

20 Apr 2023

Add-on dostarlimab boosts PFS in endometrial cancer

19 Apr 2023 by

Adding dostarlimab, an immune checkpoint inhibitor, to standard-of-care chemotherapy significantly improves progression-free survival (PFS) in patients with primary advanced or recurrent endometrial cancer, including those with dMMR-MSI-H* disease, according to the first interim analysis of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial presented at SGO 2023.

19 Apr 2023

A win for gemcitabine plus cisplatin and intensity-modulated radiotherapy in vulvar cancer

17 Apr 2023 by

The use of gemcitabine concurrently with cisplatin and intensity-modulated radiation therapy appears to improve response and prolong progression-free survival in women with locally advanced vulvar cancer not amenable to surgical resection, according to the results of the phase II NRG Oncology Trial 279 (NRG-GOG-0279) presented at SGO 2023.

17 Apr 2023

Add-on immunotherapy improves PFS in 1L advanced or recurrent endometrial cancer

17 Apr 2023 by

Adding dostarlimab or pembrolizumab to standard first-line (1L) chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, two phase III trials have shown.

17 Apr 2023